Understanding therapeutic targets in thrombotic thrombocytopenic purpura

Intensive Care Med. 2017 Sep;43(9):1398-1400. doi: 10.1007/s00134-016-4662-3. Epub 2017 Jan 23.
No abstract available

Keywords: ADAMTS13 Deficiency; Eculizumab; High Molecular Weight Multimers; Thrombotic Thrombocytopenic Purpura; Thrombotic Thrombocytopenic Purpura Patient.

MeSH terms

  • ADAMTS13 Protein / deficiency
  • ADAMTS13 Protein / immunology
  • ADAMTS13 Protein / therapeutic use
  • Autoantibodies* / blood
  • Autoantibodies* / drug effects
  • Autoantibodies* / immunology
  • Clinical Trials as Topic
  • Critical Care / methods
  • Humans
  • Immunologic Factors / therapeutic use*
  • Intensive Care Units
  • Plasma Exchange*
  • Purpura, Thrombotic Thrombocytopenic* / blood
  • Purpura, Thrombotic Thrombocytopenic* / immunology
  • Purpura, Thrombotic Thrombocytopenic* / mortality
  • Purpura, Thrombotic Thrombocytopenic* / therapy
  • Recurrence

Substances

  • Autoantibodies
  • Immunologic Factors
  • ADAMTS13 Protein